Sponsor-to-sponsor deals drive pharma services

Private equity is still spending heavily on pharma services — but mostly on existing platforms rather than creating new ones, per PitchBook data.

State of play: Deal activity is skewed heavily toward buyouts and add-ons rather than earlier-stage growth investment.